Pharmixon is a Biotechnology venture active in creating innovative therapeutics focused in Onco-Channelopathies.
Abnormal expression of an Ion Channel contributes to the dysregulation of a number of cellular functions such as cell signalling, membrane current, sensitivity to mechanical stimuli as well as modulation of micro-environmental functionalities via inter-cellular signalling.
Our particular interest is on Voltage-Gated Calcium and Potassium Channels which have been shown to be altered in several tumor types to include Prostate, Breast, Brain, Lung and Colorectal. Abnormal expression of Calcium and Potassium channel regulatory subunits may lead to uncontrolled proliferation and the development of a metastatic phenotype.
Pharmixon is developing small molecules and biologics able to block Calcium and Potassium Channel-derived malignancies which can thenstop the oncogenic re-programming when used alone or in combination with Standard of Care (SoC) therapeutics.